FORMULATION AND ADVANCEMENT OF NEW POTENTIAL THERAPIES FOR ALZHEIMER’S DISEASE

Authors

  • Dr. Sarita Santosh Mulik Associate Professor,Dept.of Shalakyatantra, Bharati Vidyapeeth (Deemed to be University)College of Ayurved, Pune Author
  • Dr. Santosh Shivaji Mulik Professor & HOD,Dept.of Shalakyatantra, Bharati Vidyapeeth (Deemed to be University)College of Ayurved, Pune. Author
  • Dr. Surya Prakash Gupta Professor & Director, Rajiv Gandhi Institute of Pharmacy, Faculty of Pharmaceutical Science& Technology, AKS University, Satna 485001 (MP) India Author

Keywords:

Alzheimer’s disease (AD), Neurodegenerative disorder, Cognitive decline, Novel therapeutic targets, Beta-amyloid plaques, Tau protein

Abstract

 Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and behavioural changes. Despite significant advancements in understanding the pathology of AD, effective therapies remain limited. This paper explores the formulation and advancement of new potential therapies for AD, focusing on innovative drug discovery, novel therapeutic targets, and emerging treatment strategies. Recent research highlights the development of compounds that address key pathological features of AD, including beta-amyloid plaque accumulation, tau protein hyper phosphorylation, and oxidative stress. We discuss the integration of multidisciplinary approaches, including the synthesis of novel chemical entities, the use of advanced nanotechnology, and the application of personalized medicine. Additionally, we review preclinical and clinical trial data to evaluate the efficacy, safety, and potential of these emerging therapies. Our analysis underscores the importance of continued research and innovation in the quest to develop effective treatments for AD, offering hope for improved patient outcomes and quality of life. 

Downloads

Download data is not yet available.

References

Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States

and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-

Von Strauss EM, Viitanen D, De Ronchi D, et al. Aging and the occurrence of dementia.

Arch Neurol. 1999;56:587-592.

Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence

of dementia and Alzheimer disease. Arch Gen Psychiatry. 1998; 55:809-815.

Ernst RL, Hay JW. The US economic and social costs of Alzheimer’s disease revisited. Am

J Public Health. 1994;84:1261-1264.

Max W. The economic impact of Alzheimer’s disease. Neurology. 1993;43:S6-S10.

Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E4 allele and the lifetime risk of

Alzheimer’s disease. Arch Neurol. 1995;52:1074-1079.

Statement on use of apolipoprotein E testing for Alzheimer disease. American College of

Medical Genetics/ American Society of Human Genetics Working Group on ApoE and

Alzheimer disease. JAMA. 1995;274:1627-1629.

Clarke R, Smith AD, Jobst KA, et al. Folate, vitamin B12, and serum total homocysteine

levels in confirmed Alzheimer disease. Arch Neurol. 1998;55:1449-1455.

Evans DA, Hebert LE, Beckett LA, et al. Education and other measures of socioeconomic

status and risk of incident Alzheimer disease in a defined population of older persons. Arch

Neurol. 1997;54:1399-1405.

Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer’s

disease. Ann Neurol. 1993;33:258-266.

Guo A, Cupples LA, Kurz A, et al. Head injury and the risk of AD in the MIRAGE study.

Neurology. 2000; 54:1316-1323.

Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and

Alzheimer’s disease. Neurology. 1999;52:78-84.

Kalmijn S, Launer LJ, Ott A, et al. Dietary fat intake and the risk of incident dementia in

the Rotterdam study. Ann Neurol. 1997;42:776-782.

Orgogozo J-M,Dartigues J-F, Lafont S, et al. Wine consumption and dementia in the

elderly. Rev Neurol (Paris). 1997;3:185-192.

Hendrie HC, Ogunniyi A, Hall KS, et al. Incidence of dementia and Alzheimer disease in

communities.JAMA. 2001;285:739-747.

Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive

impairment in elderly primary care patients. Ann Intern Med. 1995; 122:422-429.17. Folstein MF, Folstein SE, McHugh PR. Minimental state. J Psychiatr Res. 1975;12:189-

Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of

dementia. Neurology. 2001;56:1133-1142.

Costa PT, Williams TF, Albert MS, et al. Recognition and Initial Assessment of

Alzheimer’s Disease and Related Dementias. Rockville, Md: US Dept of Health and Human

Services, Agency for Health Care Policy and Research; 1996.

Cummings JL, Benson DF. Dementia: A Clinical Approach. 2nd ed. Boston, Mass:

Butterworth- Heinemann; 1992.

Mega M, Masterman DM, O’Connor SM, et al. The spectrum of behavioural responses in

cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol. 1999;56:1388-1393.

McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease.

Neurology. 1984; 34:939-944.

Bracco L, Gallato R, Grigoletto F, et al. Factors affecting course and survival in

Alzheimer disease. Arch Neurol. 1994;51:1213-1219.

Beard CM, Kokmen E, Sigler CA, et al. Cause of death in Alzheimer’s disease. Ann

Epidemiol. 1996; 6:195-200.

Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of

dementia (an evidencebased review). Neurology. 2001;56:1143-1153.

The National Institute on Aging and Reagan Institute Working Group on Diagnostic

Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Consensus

recommendations for the post-mortem diagnosis of Alzheimer’s disease. Neurobiol Aging.

;18:S1-S2.

Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution

of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with

Alzheimer’s disease. Cerebral Cortex. 1991;1:103-116.

Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer’s disease. Neurology.

;51:S2-S17.

Downloads

Published

2023-04-30

Issue

Vol. 9 No. 2 (2023): 9 (2) 2023

Section

Articles

License

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

How to Cite

Santosh Mulik, S., Shivaji Mulik, S., & Prakash Gupta, S. (2023). FORMULATION AND ADVANCEMENT OF NEW POTENTIAL THERAPIES FOR ALZHEIMER’S DISEASE. History of Medicine, 9(2). http://13.200.237.241/HOM/index.php/medicine/article/view/683